Assessment of 111In-Ibritumomab pretreatment imaging in 90Y-Ibritumomab radioimmunotherapy for relapsed or refractory low-grade B cell lymphoma.

被引：0
|
作者：
Kaneko, K. [1 ]
Uike, N. [1 ]
Shinozaki, K. [1 ]
Choi, I. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [21] RADIOIMMUNOTHERAPY CASES REGISTRY: RECURRENT OR REFRACTORY NON-HODGKIN LYMPHOMA TREATED WITH 90Y-IBRITUMOMAB TIUXETAN
    Gomez-Codina, J.
    Giraldo, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 232 - 232
  • [22] 90Y-ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy as a consolidation strategy in mantle cell lymphoma (MCL) patients
    Jurczak, W.
    Giza, A.
    Hubalewska-Dydejczyk, A.
    Sowa-Staszczak, A.
    Glowa, B.
    Szostek, M.
    Krochmalczyk, D.
    Wegrzyn, J.
    Knopinska-Posluszny, W.
    Zdziarska, B.
    Kyrcz-Krzemien, S.
    Poplawska, L.
    Walewski, J.
    Wrobel, T.
    Skotnicki, A. B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S168 - S168
  • [23] Radioimmunotherapy with 131I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with 90Y-Ibritumomab Tiuxetan
    Kang G.W.
    Kang H.J.
    Shin D.-Y.
    Gu H.R.
    Choi H.S.
    Lim S.M.
    Nuclear Medicine and Molecular Imaging, 2013, 47 (4) : 281 - 284
  • [24] Radioimmunotherapy with 90Y ibritumomab tiuxetan in aggressive lymphoma: evaluation of efficacy and safety in mantle cell lymphoma.
    Boni, G.
    Lorenzoni, A.
    Galimberti, S.
    Cataldi, A. G.
    Orciuolo, E.
    Cecconi, N.
    Ciuti, S.
    Petrini, M.
    Mariani, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [25] Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?
    Kazuhiro Kitajima
    Masaya Okada
    Toru Kashiwagi
    Kyoko Yoshihara
    Tazuko Tokugawa
    Akihiro Sawada
    Satoshi Yoshihara
    Yoshihiro Fujimori
    Koichiro Yamakado
    European Radiology, 2019, 29 : 3935 - 3944
  • [26] Cost-effectiveness of 90Y-ibritumomab tiuxetan (90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma.
    Thompson, S
    van Agthoven, M
    BLOOD, 2005, 106 (11) : 685A - 685A
  • [27] Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?
    Kitajima, Kazuhiro
    Okada, Masaya
    Kashiwagi, Toru
    Yoshihara, Kyoko
    Tokugawa, Tazuko
    Sawada, Akihiro
    Yoshihara, Satoshi
    Fujimori, Yoshihiro
    Yamakado, Koichiro
    EUROPEAN RADIOLOGY, 2019, 29 (07) : 3935 - 3944
  • [28] 131I-tositumomab (Bexxar) vs. 90Y-ibritumomab (Zevalin) therapy of low grade refractory/relapsed non-Hodgkin lymphoma
    Iagaru, Andrei
    Mittra, Erik
    Goris, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [29] Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era
    Naokuni Uike
    Ilseung Choi
    Mariko Tsuda
    Shojirou Haji
    Kousuke Toyoda
    Youko Suehiro
    Yasunobu Abe
    Toshinobu Hayashi
    Hirofumi Sawamoto
    Koichiro Kaneko
    Mototsugu Shimokawa
    Makoto Nakagawa
    International Journal of Hematology, 2014, 100 : 386 - 392
  • [30] Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era
    Uike, Naokuni
    Choi, Ilseung
    Tsuda, Mariko
    Haji, Shojirou
    Toyoda, Kousuke
    Suehiro, Youko
    Abe, Yasunobu
    Hayashi, Toshinobu
    Sawamoto, Hirofumi
    Kaneko, Koichiro
    Shimokawa, Mototsugu
    Nakagawa, Makoto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (04) : 386 - 392
12345